2026 Specialty Measure Set

2026 MIPS Quality Measures for Dermatology

The 11 MIPS quality measures designated by CMS for the Dermatology specialty set. These are the measures dermatology specialists are most likely to report on, though any MIPS-eligible measure can be submitted.

11measures
8high priority
11with benchmarks
6topped out
ID ↑Measure eCQMType Status
MIPS 130Documentation of Current Medications in the Medical RecordCMS68v15High PriorityTopped Out
MIPS 176Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy—ProcessTopped Out
MIPS 226Preventive Care and Screening: Tobacco Use: Screening and Cessation InterventionCMS138v14ProcessTopped Out
MIPS 317Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up DocumentedCMS22v14ProcessTopped Out
MIPS 374Closing the Referral Loop: Receipt of Specialist ReportCMS50v14High PriorityTopped Out
MIPS 410Psoriasis: Clinical Response to Systemic Medications—High PriorityBenchmark
MIPS 440Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician—High PriorityTopped Out
MIPS 485Psoriasis – Improvement in Patient-Reported Itch Severity—High PriorityBenchmark
MIPS 486Dermatitis – Improvement in Patient-Reported Itch Severity—High PriorityBenchmark
MIPS 503Gains in Patient Activation Measure (PAM) Scores at 12 Months—High PriorityBenchmark
MIPS 509Melanoma: Tracking and Evaluation of Recurrence—High PriorityBenchmark

All Specialty Sets

Need help selecting measures?

VBCA's clinical policy team helps practices choose the right measure mix based on patient population, benchmark opportunity, and program requirements.

Get a measure-mix review →